Product Name:Sermorelin Acetate
Cas No:114466-38-5
Molar Mass:3417.9
Chemical Formula:C151H250N44O44S
Synonyms:GHRH (1-29)
Storage:Store at -20°C
Sequence: YADAIFTNSY RKVLGQLSAR KLLQDIMSRQ QGESNQERGA RARL
target: GHRH
Purity:98%
Application: Sermorelin acetate is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the secretion of growth hormone from the pituitary gland. It is used therapeutically to treat growth hormone deficiency in children and adults. In pharmaceutical chemistry, sermorelin acetate is studied for its ability to restore normal growth hormone levels, which can help promote linear growth in children with growth hormone deficiency and improve body composition in adults. Additionally, it has been investigated for its potential anti-aging effects, such as improving skin elasticity and reducing adipose tissue accumulation. Sermorelin acetate’s mechanism of action involves binding to specific receptors on pituitary cells, stimulating the release of growth hormone in a pulsatile manner, similar to the body’s natural secretion pattern. This makes it a valuable tool in endocrinology for managing growth disorders and age-related hormonal changes.
Current Research:Sermorelin, a synthetic growth hormone-releasing hormone (GHRH), has emerged as a promising candidate for the treatment of recurrent gliomas, offering a potential solution to the challenge of therapeutic resistance in glioma patients. GHRH, a hypothalamic peptide neurohormone, regulates the release of growth hormone (GH) by acting on the growth hormone-releasing hormone receptor (GHRHR). Beyond its traditional role in regulating growth, Sermorelin has demonstrated significant anti-tumor effects, particularly in glioblastoma.
Research has shown that Sermorelin can inhibit the growth, invasion, and metastasis of glioblastoma cells both in vitro and in vivo. Studies by Jaszberenyi et al. and Schally et al. have highlighted Sermorelin’s ability to suppress tumor growth by down-regulating the expression of GHRHR, offering a promising therapeutic strategy for recurrent gliomas.
In this study, we utilized high-throughput drug screening techniques and analyzed sequencing data from the Chinese Glioma Genome Atlas (CGGA) database to identify Sermorelin as the most effective drug for recurrent gliomas. Through further analysis, we observed that Sermorelin was particularly effective in patients with malignant molecular phenotypes, including WHO grade IV, IDH wildtype, 1p/19q non-codeletion, and mesenchymal subtype gliomas.
Our findings also revealed a negative correlation between the Drug Resistance Score (DRS) of Sermorelin and cell proliferation and immune function. Notably, patients with lower DRS showed higher expression of immune checkpoints and macrophage infiltration, indicating increased sensitivity to Sermorelin. Furthermore, patients who had received radiotherapy and chemotherapy exhibited lower DRS, suggesting enhanced sensitivity to Sermorelin following conventional treatments.
By leveraging large-scale sequencing data and clinical characteristics, our study provides a novel approach to drug screening for recurrent gliomas. Sermorelin’s ability to penetrate the blood-brain barrier with minimal side effects makes it an ideal candidate for recurrent glioma treatment. Moreover, our analysis indicates that patients with more aggressive phenotypes may benefit most from Sermorelin therapy, offering new hope for improved outcomes in this challenging patient population.
Overall, our research not only identifies Sermorelin as a promising therapeutic option for recurrent gliomas but also demonstrates the potential of data-driven approaches to personalized cancer treatment. By combining molecular profiling with drug sensitivity analysis, we can optimize treatment strategies and enhance patient outcomes in glioma and potentially other cancer types.
Chang, Y., Huang, R., Zhai, Y., Huang, L., Feng, Y., Wang, D., … & Hu, H. (2021). A potentially effective drug for patients with recurrent glioma: Sermorelin. Annals of Translational Medicine, 9(5).
